Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9940899 | 0.87 | KDM4E (0.32) | LPLLIPG | |
| SCHEMBL18288179 | 0.86 | BACE1 (0.31) | — | |
| SCHEMBL781799 | 0.81 | L3MBTL1 (0.33) | LPLLIPG | |
| SCHEMBL30203974 | 0.81 | L3MBTL1 (0.33) | LPLLIPG | |
| SCHEMBL9940458 | 0.78 | LIPE (0.35) | LIPEIDO1TDO2LPLLIPG | |
| SCHEMBL9977811 | 0.77 | LPL (0.33) | IDO1TDO2LPLLIPG | |
| SCHEMBL22894144 | 0.76 | LPL (0.32) | IDO1TDO2LPLLIPG | |
| SCHEMBL30242941 | 0.74 | TDP1 (0.31) | — | |
| SCHEMBL14685109 | 0.74 | TDP1 (0.31) | — | |
| SCHEMBL31540060 | 0.74 | MAPK1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117362318-A | PB2 inhibitor and preparation method and application thereof | 西藏海思科制药有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230339943-A1 | ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVES | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| CN-115698011-B | PB2 inhibitor and preparation method and application thereof | 四川海思科制药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-11725009-B2 | Anti-influenza virus pyrimidine derivative | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2023-08-15 | — | — | US | disclosed |
| EP-4180434-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| CN-115698011-A | PB2 inhibitor and preparation method and application thereof | 四川海思科制药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-112771048-B | Inhibitors of influenza virus replication and intermediates and uses thereof | 南京药石科技股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-112771048-A | Inhibitors of influenza virus replication and intermediates and uses thereof | 南京药石科技股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| EP-2739623-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2014-06-11 | — | — | EP | disclosed |
| US-20140005197-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-02 | — | — | US | disclosed |
| US-20140005192-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2651941-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2651940-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2013019828-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2013019828-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2012083121-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083117-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083117-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11725009-B2 | Anti-influenza virus pyrimidine derivative | ENTPD5, NUDT15, ITPA | LIPE 4653/4885IDO1 38/4885TDO2 1311/4885 |
| US-20230265107-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP11B2, WEE2, CYP11B1 | LIPE 4814/4885IDO1 97/4885TDO2 18/4885 |
| US-20140005192-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | LIPE 2571/4885IDO1 23/4885TDO2 2567/4885 |
| US-20230339943-A1 | ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVES | ENTPD5, NUDT1, ITPA | LIPE 4680/4885IDO1 45/4885TDO2 1266/4885 |
| US-20140005197-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | LIPE 2571/4885IDO1 23/4885TDO2 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.